Gilead Sciences has filed for conditional approval in the EU of its investigational antiviral drug, remdesivir, for treating COVID-19. The review could be completed in weeks.
The European Medicines Agency announced today that it had received the application and said that its decision on whether to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?